Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures

Martin E Brown1 Department of Neurology;2 Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky, USA

Rif S El-Mallakh1 Department of Neurology;2 Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky, USACorrespondence[email protected]

Figures & data

Figure 1 Eslicarbazepine is formed by reduction of the acetate salt (shown on the right) or may be found as the predominant (4:1) active metabolite of oxcarbazepine (middle). Carbamazepine and its active epoxide metabolite are shown on the left. Reprinted with permission from Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007;4:88–96.^Citation12 Copyright © 2007 Elsevier.

Table 1 Summary of potential pharmacokinetic interactions between eslicarbazepine and other medications^Citation29

Download CSV Display Table

Table 2 Summary of percentage of adverse events across two placebo-controlled trials^{Citation27,Citation33}

Download CSV Display Table

Table 3 Eslicarbazepine levels as a function of dose^Citation27

Download CSV Display Table

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures

Table 1 Summary of potential pharmacokinetic interactions between eslicarbazepine and other medications^Citation29

Table 2 Summary of percentage of adverse events across two placebo-controlled trials^{Citation27,Citation33}

Table 3 Eslicarbazepine levels as a function of dose^Citation27

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures

Figures & data

Table 1 Summary of potential pharmacokinetic interactions between eslicarbazepine and other medicationsCitation29

Table 2 Summary of percentage of adverse events across two placebo-controlled trialsCitation27,Citation33

Table 3 Eslicarbazepine levels as a function of doseCitation27

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1 Summary of potential pharmacokinetic interactions between eslicarbazepine and other medications^Citation29

Table 2 Summary of percentage of adverse events across two placebo-controlled trials^{Citation27,Citation33}

Table 3 Eslicarbazepine levels as a function of dose^Citation27